CCT241736
CAS No. 1402709-93-6
CCT241736 ( CCT241736; CCT-241736; CCT 241736 )
产品货号. M17277 CAS No. 1402709-93-6
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3.
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥446 | 有现货 |
|
10MG | ¥721 | 有现货 |
|
25MG | ¥1450 | 有现货 |
|
50MG | ¥2811 | 有现货 |
|
100MG | ¥4204 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CCT241736
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3.
-
产品描述CCT241736 is a potent and orally active and dual FLT3-Aurora inhibitor. CCT241736 has IC50 values against FLT3, Aurora A and Aurora B of 0.035, 0.015 and 0.1 μM respectively. CCT241736 inhibits a wide range of FLT3 mutants, including FLT3-ITD, -D835Y, -D835H, -K663Q and -N841I. In cellular assays, CCT241736 inhibits viability of the human FLT3-ITD positive AML cell lines MOLM-13 and MV-4;11 with EC50 values of 0.1 and 0.27
-
同义词CCT241736; CCT-241736; CCT 241736
-
通路GPCR/G Protein
-
靶点Dopamine Receptor
-
受体FLT3;Aurora Kinase
-
研究领域——
-
适应症——
化学信息
-
CAS Number1402709-93-6
-
分子量456.37
-
分子式C22H23Cl2N7
-
纯度98%
-
溶解度DMSO : 75 mg/mL 164.34 mM; H2O : < 0.1 mg/mL
-
SMILESCc5nn(C)cc5c3nc4ncc(Cl)c(N2CCN(Cc1ccc(Cl)cc1)CC2)c4n3
-
化学全称6-chloro-7-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Bavetsias V,etal. J Med Chem. 2012 Oct 25;55(20):8721-34.
产品手册
关联产品
-
E6446
E6446 inhibits Toll-like receptor (TLR)7 and 9 signaling. E6446 works in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro.
-
NMI 8739
NMI 8739 is an agonist of D2 autoreceptor. NMI 8739 reduces NO production and elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 release.
-
FIIN-2
FIIN-2, an irreversible, pan-FGFR inhibitor, inhibits FGFR1/2/3/4 with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM, respectively.